Phase 3 Psoriatic Arthritis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with juvenile psoriatic arthritis (a type of arthritis linked to psoriasis in children and young people) for at least 3 months before the screening visit, based on recognised international criteria.
- People who have active arthritis in 3 or more joints at both the screening and baseline visits, meaning joints that are swollen (not due to a deformity), or have limited movement along with pain or tenderness.
- People whose arthritis has not responded well enough to at least one standard arthritis medication — such as methotrexate, sulfasalazine, leflunomide, or hydroxychloroquine — after taking it for at least 2 months at the highest tolerated dose, or who could not tolerate one of these medications.
Who may not be able to join:
- People who have another autoimmune or rheumatic condition, including certain other forms of juvenile idiopathic arthritis (such as systemic JIA, polyarticular JIA, oligoarticular JIA, enthesitis-related arthritis, or undifferentiated JIA), or an overlap syndrome involving more than one such condition.
- People whose arthritis has previously not responded adequately to medications from the anti-TNF or IL-23 inhibitor classes of treatments (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: ABBVIE INC., AbbVie
Phone: 844-663-3742
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Participants who Achieve >= 30% Improvement in Juvenile Idiopathic Arthritis American College of Rheumatology Response Criteria (JIA-ACR 30); Number of Participants with Adverse Events (AEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.